Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

Volume: 177, Pages: 106241 - 106241
Published: Feb 1, 2021
Abstract
ObjectiveThe soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical...
Paper Details
Title
Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
Published Date
Feb 1, 2021
Volume
177
Pages
106241 - 106241
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.